Results 61 to 70 of about 3,402 (156)

58例低级别脑胶质瘤术后放化疗疗效及预后相关因素分析 Analysis of the Curative Effect and Prognosis of 58 Cases of Low-Grade Gliomas Treated by Postoperative Chemo-Radiotherapy

, 2017
Mang Zhang, Wei-li Wu, F. Jin, Jinhua Long, Yuanyuan Li, Xiuling Luo, X. Gong, Xiaoxiao Chen, Chunli Yang, Hongtao Zhao   +9 more
semanticscholar   +1 more source

[A predictive model for survival outcomes of glioma patients based on multi-parametric, multi-regional MRI radiomics features and clinical features]. [PDF]

Nan Fang Yi Ke Da Xue Xue Bao
Huang X, Chen F, Zhang Y, Liang S.
europepmc   +1 more source

Angiopep-2修饰的Ag 2 S量子点用于近红外二区脑胶质瘤成像

, 2018
徐毅, 赵彦, 张叶俊, 崔之芬, 王丽华, 樊春海, 高基民, 孙艳红   +7 more
semanticscholar   +1 more source

miR-126下调MMP-2抑制人脑胶质瘤细胞侵袭

, 2012
陈寿仁, 王占祥, 沈上杭, 谭国伟, 刘希尧, 朱宏伟   +5 more
openalex   +2 more sources

[Predicting cerebral glioma enhancement pattern using a machine learning-based magnetic resonance imaging radiomics model]. [PDF]

Nan Fang Yi Ke Da Xue Xue Bao
He H, Guo E, Meng W, Wang Y, Wang W, He W, Wu Y, Yang W.   +7 more
europepmc   +1 more source

脑胶质瘤靶向脂质体的制备和表征 Preparation and Characterization of Glioma Targeted Liposomes

, 2017
Wei-e Han, A. Hu, Dajing Yao, Guang Yin
semanticscholar   +1 more source

PDGFBB与VEGF在人脑胶质瘤中的表达及临床意义

, 2005
夏学巍, 郭宗泽, 苏长保
openalex   +1 more source

胶质瘤对替莫唑胺耐药机制的研究进展

Zhongguo shiyan zhenduanxue
神经胶质瘤是最常见和最致命的脑肿瘤之一。手术切除后放疗加化疗是目前神经胶质瘤患者的主要治疗手段。然而，由于胶质瘤细胞对基因毒性治疗的耐药性，以及肿瘤的异质性的本质，极大地限制了胶质瘤治疗的疗效。本文从癌症干细胞、细胞凋亡逃逸和代谢重编程等角度，阐述了促进神经胶质瘤替莫唑胺耐药的相关机制，为神经胶质瘤的靶向治疗提供新的研究思路和策略。
齐方明, 贺宜春, 周孟瑒, 王书涛, 许华丹   +4 more
doaj  

脑动脉灌注 VM26联合口服 CCNU 治疗脑胶质瘤

Zhongshan Daxue xuebao. Yixue kexue ban, 1998
目的: 比较替尼泊甙(VM26)和卡氮芥( BCNU)分别联合口服环己亚硝脲( CCNU)治疗脑胶质瘤的疗效。方法: 对 27 例脑胶质瘤手术切除后, 采用微导管进行超选择脑动脉灌注法分组灌注 VM26(A 组)和 BCNU( B 组) ,并且两者联合口 服 CCNU, 化疗后,依肿瘤实际体积的变化和平均生存时间观察疗效。结果: A 组有效率 12/15, B 组有效率 4/12,A 组和 B 组 平均生存时间分别为 25. 3 个月和 21. 1 个月(P
doaj  

[circ_EPHB4 synergizes with YTHDF3 to promote glioma progression <i>via</i> m⁶A-dependent stabilization of Wnt3]. [PDF]

Nan Fang Yi Ke Da Xue Xue Bao
Jin C, Liu J, Liu B, Fei X, Liao Y.
europepmc   +1 more source